CRIS · Curis Inc · Earnings Calls, Transcripts & Webcasts
$0.43
-0.04 (-9.03%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
Market Cap
$4.06M
Shares
9.51M
Volume · Nov 20
531.09K
Avg daily vol (3M)
4.27M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Curis Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Curis Inc (CRIS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
Curis Inc (CRIS) Q3 2026 Earnings Call Transcript
Positive tone
CLL proof-of-concept study
PCNSL registrational enrollment
PCNSL clinical efficacy
Net income
−$8.12M
Diluted EPS
$-1.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Curis Inc (CRIS) Q1 2026 Earnings Call Transcript
Positive tone
TakeAim CLL proof-of-concept study
TakeAim Lymphoma / PCNSL registrational study
Financial position and runway
Revenue
$0
▼ 100% YoY Diluted EPS
$-25.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Curis Inc (CRIS) Q4 2025 Earnings Call Transcript
Confident tone
Emavusertib + ibrutinib in CLL proof-of-concept
TakeAim Lymphoma / PCNSL registrational study
Resource prioritization and AML deferral
Revenue
$1.14M*
▼ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Curis Inc (CRIS) Q3 2025 Earnings Call Transcript
Positive tone
CLL Program Expansion
PCNSL (Primary CNS Lymphoma) TakeAim Lymphoma Study
AML Triplet Study (Aza-Ven + Emavusertib)
Revenue
$3.18M
▲ 8.4% YoY Diluted EPS
$-9.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Curis Inc (CRIS) Q2 2025 Earnings Call Transcript
Confident tone
TakeAim Lymphoma / PCNSL study
CLL proof-of-concept study
AML relapsed/refractory registrational study
Revenue
$2.75M
▲ 8% YoY Diluted EPS
$-13.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Curis Inc (CRIS) Q1 2025 Earnings Call Transcript
Positive tone
Emavusertib in PCNSL (TakeAim Lymphoma study)
Emavusertib in AML
Broader NHL / pipeline expansion strategy
Revenue
$2.38M
▲ 14.1% YoY Diluted EPS
$-25.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Curis Inc (CRIS) Q4 2024 Earnings Call
Revenue
$3.35M*
▲ 24.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Curis Inc (CRIS) Q3 2024 Earnings Call Transcript
Positive tone
PCNSL study with ibrutinib combination
FDA regulatory engagement and accelerated approval
TakeAim Leukemia (AML) data
Revenue
$2.93M
▲ 3.5% YoY Diluted EPS
$-34.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Curis Inc (CRIS) Q2 2024 Earnings Call Transcript
Confident tone
TakeAim Leukemia study in AML
TakeAim Lymphoma / PCNSL study
IRAK4 mechanism and differentiation
Revenue
$2.55M
▲ 15.9% YoY Diluted EPS
$-40.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Curis Inc (CRIS) Q1 2024 Earnings Call Transcript
Confident tone
FLT3 mutation benchmark positioning
Emavusertib clinical progress in AML and lymphoma
Regulatory path and FDA discussions
Revenue
$2.09M
▼ 9.2% YoY Diluted EPS
$-41.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Curis Inc (CRIS) Q4 2023 Earnings Call Transcript
Confident tone
Emavusertib leukemia program (AML)
Primary CNS lymphoma (PCNSL) program
Solid tumor expansion (melanoma/IIT)
Revenue
$2.70M*
▼ 6.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Curis Inc (CRIS) Q3 2023 Earnings Call Transcript
Revenue
$2.83M
▲ 0.3% YoY Diluted EPS
$-42.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Curis Inc (CRIS) Q2 2023 Earnings Call Transcript
Revenue
$2.20M
▼ 8.2% YoY Diluted EPS
$-49.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Curis Inc (CRIS) Q1 2023 Earnings Call Transcript
Revenue
$2.30M
▲ 11.7% YoY Diluted EPS
$-47.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Curis Inc (CRIS) Q4 2022 Earnings Call Transcript
Revenue
$2.89M*
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Curis Inc (CRIS) Q3 2022 Earnings Call Transcript
Revenue
$2.83M
▼ 7% YoY Diluted EPS
$-56.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Curis Inc (CRIS) Q2 2022 Earnings Call Transcript
Revenue
$2.39M
▲ 4.7% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Curis Inc (CRIS) Q1 2022 Earnings Call Transcript
Revenue
$2.06M
▼ 6% YoY Diluted EPS
$-3.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Curis Inc (CRIS) Q4 2021 Earnings Call Transcript
Revenue
$3.13M*
▲ 3.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Curis Inc (CRIS) Q3 2021 Earnings Call Transcript
Revenue
$3.04M
▲ 10.8% YoY Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Curis Inc (CRIS) Q2 2021 Earnings Call Transcript
Revenue
$2.29M
▼ 3.1% YoY Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Curis Inc (CRIS) Q1 2021 Earnings Call Transcript
Revenue
$2.19M
▼ 19.2% YoY Diluted EPS
$-2.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Curis Inc (CRIS) Q4 2020 Earnings Call Transcript
Revenue
$3.02M
▼ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Curis Inc (CRIS) Q3 2020 Earnings Call Transcript
Revenue
$2.74M
▼ 4% YoY Diluted EPS
$-2.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Curis Inc (CRIS) Q2 2020 Earnings Call Transcript
Revenue
$2.36M
▲ 12.7% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Curis Inc (CRIS) Q1 2020 Earnings Call Transcript
Revenue
$2.71M
▲ 53.3% YoY Diluted EPS
$-5.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-19
Curis Inc (CRIS) Q4 2019 Earnings Call
Revenue
$3.29M
▲ 19.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts
Key facts
CIK
1108205
CUSIP
231269408
13F (30d)
52 filings
29 filers
Visit website
Investor relations